Product
Help
Pricing
About
Jobs
Log in
Get started
Award
Add to collection
CA016672
Funder:
AstraZeneca
Funded outputs count:
29
Funder award ID:
CA016672
OpenAlex ID:
G6607361216
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2025
·
Jennifer A. Woyach
, Lugui Qiu
, et al.
·
Journal of Clinical Oncology
·
32
PDF
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy
2025
·
Erez N. Baruch
, Frederico O. Gleber-Netto
, et al.
·
Nature
·
156
Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia
2025
·
William G. Wierda
, Barbara F. Eichhorst
, et al.
·
Blood
·
3
PDF
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial
2024
·
Nicholas J Short
, Daniel Nguyen
, et al.
·
The Lancet Haematology
·
27
PDF
An atlas of epithelial cell states and plasticity in lung adenocarcinoma
2024
·
Guangchun Han
, Ansam Sinjab
, et al.
·
Nature
·
197
Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses
2023
·
Nitin Jain
, Philip Thompson
, et al.
·
Blood
·
3
PDF
Undetectable MRD Status in Patients with R/R CLL/SLL with Stable Disease after Lisocabtagene Maraleucel Treatment: Exploratory Analysis of the TRANSCEND CLL 004 Study
2023
·
Eniko Papp
, Sahar Ansari
, et al.
·
Blood
PDF
Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study
2023
·
Paolo Ghia
, William G. Wierda
, et al.
·
Blood
·
42
PDF
Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL
2023
·
Chaitra S Ujjani
, Ted Gooley
, et al.
·
Blood
PDF
Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment
2023
·
Sanja Dacic
, Xuanye Cao
, et al.
·
Journal of Thoracic Oncology
·
20
PDF
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD
2023
·
Philip A. Thompson
, Michael J. Keating
, et al.
·
Leukemia
·
11
PDF
Data from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
2023
·
Shannon N. Westin
, Marilyne Labrie
, et al.
PDF
Spatial PD‐L1, immune‐cell microenvironment, and genomic copy‐number alteration patterns and drivers of invasive‐disease transition in prospective oral precancer cohort
2023
·
William N. William
, Jianjun Zhang
, et al.
·
Cancer
·
16
PDF
Physician Perspectives on Telemedicine in Radiation Oncology
2022
·
Sean Maroongroge
, Brian De
, et al.
·
Advances in Radiation Oncology
·
11
PDF
Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic CTNNB1 mutation on recurrence-free survival
2022
·
Katherine C Kurnit
, Bryan M Fellman
, et al.
·
International Journal of Gynecological Cancer
·
14
PDF
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
2021
·
Shannon N. Westin
, Marilyne Labrie
, et al.
·
Clinical Cancer Research
·
95
PDF
A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores
2021
·
Takeo Fujii
, Hiroko Masuda
, et al.
·
Breast Cancer Research and Treatment
·
10
PDF
Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing
2021
·
Ansam Sinjab
, Guangchun Han
, et al.
·
Cancer Discovery
·
150
PDF
Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes
2021
·
Stefan C. Dentro
, Ignaty Leshchiner
, et al.
·
Cell
·
580
PDF
Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC
2020
·
Olsi Gjyshi
, Ting Xu
, et al.
·
Journal of Thoracic Oncology
·
48
PDF
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC
2020
·
James W. Welsh
, John V. Heymach
, et al.
·
Journal of Thoracic Oncology
·
111
Comparing Radiation Modalities with Trimodality Therapy Using Total Toxicity Burden
2020
·
Denái R. Milton
, Steven H. Lin
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
2
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
2018
·
Jianfeng Shen
, Wei Zhao
, et al.
·
Cancer Research
·
639
PDF
Faculty Opinions recommendation of Laparoscopic surgical algorithm to triage the timing of tumor reductive surgery in advanced ovarian cancer.
2018
·
Eva Chalas
·
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
PDF
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers
2018
·
Jorge Cortes
, Kenji Tamura
, et al.
·
British Journal of Cancer
·
127
PDF
Show more works
View as search